Rep. Gilbert Ray Cisneros, Jr. Unloads Shares of Illumina, Inc. (NASDAQ:ILMN)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Illumina, Inc. (NASDAQ:ILMN). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Illumina stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

Illumina Stock Down 1.6%

Shares of Illumina stock traded down $3.38 during trading on Thursday, hitting $209.55. 1,726,386 shares of the stock were exchanged, compared to its average volume of 2,186,053. The stock has a market cap of $31.68 billion, a price-to-earnings ratio of 36.07, a price-to-earnings-growth ratio of 2.92 and a beta of 1.46. The firm’s 50-day moving average price is $249.32 and its 200 day moving average price is $179.36. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.63 and a quick ratio of 2.05.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same quarter last year, the company earned $1.34 EPS. The business’s quarterly revenue was up 4.2% on a year-over-year basis. As a group, analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Insider Activity at Illumina

In related news, Director Keith A. Meister sold 98,833 shares of the stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total value of $21,433,912.71. Following the completion of the transaction, the director owned 208,826 shares of the company’s stock, valued at approximately $45,288,094.62. This represents a 32.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Scott D. Ericksen sold 267 shares of the stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total value of $58,141.92. Following the completion of the transaction, the chief accounting officer directly owned 14,029 shares of the company’s stock, valued at $3,054,955.04. This represents a 1.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,881,899 shares of company stock valued at $415,905,954 in the last ninety days. 2.90% of the stock is owned by corporate insiders.

Illumina News Roundup

These are some of the ILMN news items that stood out recently:

• Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Neutral Sentiment: Illumina’s chief accounting officer sold 267 shares under a pre-arranged Rule 10b5-1 trading plan, a relatively small transaction that may be less informative about the executive’s view of the company. SEC filing

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wall Street Zen cut Illumina from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Citigroup raised their price objective on Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a research note on Monday, November 2nd. Stifel Nicolaus lifted their price objective on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Royal Bank Of Canada boosted their target price on Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Finally, Argus upped their target price on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Hold” and an average target price of $244.24.

Hedge Funds Weigh In On Illumina

A number of large investors have recently modified their holdings of ILMN. Fiduciary Financial Advisors acquired a new stake in shares of Illumina in the second quarter valued at about $26,000. MCF Advisors LLC lifted its position in Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 100 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. acquired a new position in Illumina during the 3rd quarter worth approximately $31,000. Keating Financial Advisory Services Inc. acquired a new position in Illumina during the 2nd quarter worth approximately $32,000. Finally, Rakuten Securities Inc. purchased a new position in Illumina in the 2nd quarter worth approximately $33,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.